Iqvia Holdings Inc (IQV) Stock Price, Quote & News

Company Profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 919 998 2000

Website: www.iqvia.com

Address:

2400 Ellis Road, Durham, United States

dukewill Mar. 9 at 1:59 PM

$IQV Market shakeout not yet complete

0 · Reply

TheClockworkGroup Feb. 27 at 10:53 PM

$IQV #NYSE | The markets are unpredictable, but with #WaveE, one of our cutting-edge #AI-driven #algorithmic #breakout #daytrading strategies, you too can make calculated trades like a pro! Scalped profits of +$5,422.06 trading #IQVIAHoldingsInc., $IQV shares today! Experience 100% automation and compatibility with @MultiCharts, @NinjaTrader, @TradeStation & @TradingView...

0 · Reply

LandonCapital Feb. 25 at 5:30 PM

$IQV https://landoncapital.net/iqvia-nyse-iqv-to-acquire-drug-discovery-assets/

0 · Reply

d_risk Feb. 17 at 4:38 PM

$IQV $HLMN - Hillman Solutions Corp - 10K - Updated Risk Factors HLMN’s 2026 10-K risk revamp spotlights heavy reliance on two big-box customers post-True Value bankruptcy, deeper tariffs/China-Taiwan and international trade exposure, new ERP and cyber/IT vulnerabilities, tighter focus on inventory and working capital, more granular leverage and liquidity constraints amid volatile capital markets, and expanded IP and FX risks, while trimming M&A, legal proceedings, and seasonal/weather risk detail. #IndustrialHardware #CustomerConcentrationRisk #TradeTariffs #CybersecurityVulnerabilities #FinancialLiquidity 🟢 Added 🟠 Removed https://d-risk.ai/HLMN/10-K/2026-02-17

0 · Reply

d_risk Feb. 17 at 3:57 PM

$IQV - IQVIA Holdings Inc - 10K - Updated Risk Factors IQVIA’s 10-K risk section is now longer, more detailed, and more tech- and regulation-focused: it trims multiple execution, M&A, client concentration, tax, and capital markets risks while expanding disclosures on AI, data and third‑party dependencies, cyber/IT systems, IP protection, international operations, sustainability, restructuring, leverage covenants, and shareholder rights. #HealthcareTechnology #AIIntegration #CybersecurityRisks #RegulatoryCompliance #InternationalOperations 🟢 Added 🟠 Removed https://d-risk.ai/IQV/10-K/2026-02-17

0 · Reply

UgoGreg Feb. 14 at 4:44 PM

$IQV https://youtu.be/m61diFB2Pag

0 · Reply

Estimize Feb. 9 at 3:06 PM

Wall St is expecting 2.84 EPS for $IQV Q1 [Reporting 04/23 BMO] http://www.estimize.com/intro/iqv?chart=historical&metric_name=eps&utm_cont

0 · Reply

ZacksResearch Feb. 5 at 5:52 PM

$IQV just delivered a clean Q4 beat — and guidance is turning heads 👀 Q4 2025 earnings and revenues topped estimates with double-digit Y/Y sales growth, driven by strong segment gains, alongside upbeat 2026 revenue guidance. See what this could mean next 👉 https://www.zacks.com/stock/news/2830156/iqvia-q4-earnings-revenues-beat-estimates-increase-yy?cid=sm-stocktwits-2-2830156-teaser-32194&ADID=SYND_STOCKTWITS_TWEET_2_2830156_TEASER_32194

0 · Reply

ZacksResearch Feb. 5 at 4:52 PM

$IQV crushes Q4 earnings & revenue estimates! 📈 💰 Adjusted EPS jumped 9.6% YoY to $3.42, outpacing the Zacks Consensus Estimate. 📊 Total revenues rose 10.3% YoY to $4.4B, beating estimates by 2.8%. 🚀 Strong segmental growth drives performance, with R&D and Tech segments meeting expectations while Contract Sales and Medical Solutions surpassed them. Discover what's fueling IQVIA's momentum 👉 https://www.zacks.com/stock/news/2830156/iqvia-q4-earnings-revenues-beat-estimates-increase-yy?cid=sm-stocktwits-2-2830156-body-32157&ADID=SYND_STOCKTWITS_TWEET_2_2830156_BODY_32157

0 · Reply

1986iamwallstreet Feb. 5 at 2:38 PM

$IQV flush city 🩸🩸🩸🩸🩸🩸

0 · Reply

IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 4:15 PM EST - 6 days ago

IQVIA CEO to Speak at Leerink Partners 2026 Global Healthcare Conference

Feb 28, 2026, 5:50 AM EST - 9 days ago

IQVIA Holdings: Still Exceeding Expectations As A Stealth Compounder

Feb 27, 2026, 4:47 PM EST - 9 days ago

IQVIA Releases its 2025 Sustainability Report

Feb 26, 2026, 3:07 PM EST - 10 days ago

IQVIA Holdings Inc. (IQV) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

Feb 25, 2026, 7:00 AM EST - 12 days ago

IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities

Feb 24, 2026, 9:01 AM EST - 13 days ago

10 stocks Wall Street expects to roar back after dropping at least 20% in 2026

APP BKNG COF CSGP KKR NOW ORCL

Feb 18, 2026, 4:15 PM EST - 18 days ago

IQVIA to Speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day

Feb 12, 2026, 5:07 AM EST - 25 days ago

Oakmark Global All Cap Strategy Q4 2025 Performance Review

BABA CNH

Feb 10, 2026, 8:00 AM EST - 27 days ago

IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions

Feb 5, 2026, 3:24 PM EST - 4 weeks ago

IQVIA Holdings Inc. (IQV) Q4 2025 Earnings Call Transcript

Feb 5, 2026, 9:07 AM EST - 4 weeks ago

IQVIA forecasts weak annual profit on higher interest expenses

Feb 5, 2026, 7:00 AM EST - 4 weeks ago

IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

Jan 29, 2026, 8:00 AM EST - 5 weeks ago

IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration

Jan 22, 2026, 4:05 PM EST - 6 weeks ago

IQVIA Named to the Fortune® World's Most Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year

Jan 20, 2026, 4:45 PM EST - 6 weeks ago

IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026

Dec 11, 2025, 1:56 PM EST - 3 months ago

IQVIA: Increasingly Indispensable In Drug Development

Dec 2, 2025, 8:00 AM EST - 3 months ago

IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform

Nov 12, 2025, 5:43 AM EST - 4 months ago

Oakmark Global Concentrated Strategy Q3 2025 Top Contributors And Detractors

BABA CHTR CNC CNH GOOG GOOGL

Nov 11, 2025, 2:31 PM EST - 4 months ago

IQVIA Holdings Inc. (IQV) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 2:15 AM EST - 4 months ago

Oakmark Concentrated Strategy: 6 Stocks That Raised Guidance And Drove Innovation

CRM GOOG GOOGL KDP MOH WBD

Nov 5, 2025, 4:15 PM EST - 4 months ago

Dr. William G. Kaelin Jr. joins IQVIA Board of Directors

Oct 28, 2025, 1:52 PM EDT - 4 months ago

IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 7:53 AM EDT - 4 months ago

IQVIA narrows annual profit forecast amid continued research contract cancellations

Oct 28, 2025, 7:00 AM EDT - 4 months ago

IQVIA Reports Third-Quarter 2025 Results

Oct 24, 2025, 4:30 AM EDT - 4 months ago

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FISV IVZ JNJ LRCX

Oct 21, 2025, 4:15 PM EDT - 4 months ago

IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025

Sep 30, 2025, 4:15 PM EDT - 5 months ago

IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

Sep 26, 2025, 9:40 AM EDT - 5 months ago

ILMN Stock vs. IQV Stock

ILMN

Sep 16, 2025, 8:00 AM EDT - 6 months ago

IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships

Sep 11, 2025, 2:00 AM EDT - 6 months ago

IQVIA: A Positive Long-Term Outlook Despite Trump Legislation

Sep 10, 2025, 8:00 AM EDT - 6 months ago

IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management

Sep 2, 2025, 9:41 AM EDT - 6 months ago

IQVIA names Michael Fedock as financial chief

Sep 2, 2025, 9:00 AM EDT - 6 months ago

IQVIA Announces CFO Transition in Early 2026

Aug 28, 2025, 8:00 AM EDT - 6 months ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

FHTX MRNA SANA

Aug 19, 2025, 12:00 PM EDT - 7 months ago

The Big 3: BLDR, IQV, LOW

BLDR LOW

Aug 18, 2025, 9:00 AM EDT - 7 months ago

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

VEEV

Jul 22, 2025, 5:40 PM EDT - 8 months ago

IQVIA: Q2 Earnings Exceeded My Expectations

Jul 22, 2025, 2:00 PM EDT - 8 months ago

IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 8:42 AM EDT - 8 months ago

IQVIA beats quarterly estimates on resilient demand for healthcare analytics

Jul 22, 2025, 7:00 AM EDT - 8 months ago

IQVIA Reports Second-Quarter 2025 Results

Jul 16, 2025, 7:54 AM EDT - 8 months ago

IQVIA: Competition Is Creating More Challenges Over The Long Haul

Jul 1, 2025, 7:00 AM EDT - 8 months ago

IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

Jun 16, 2025, 9:00 AM EDT - 9 months ago

IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement'

Jun 11, 2025, 7:00 AM EDT - 9 months ago

IQVIA Launches New AI Agents for Life Sciences and Healthcare

Jun 10, 2025, 2:23 PM EDT - 9 months ago

IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?

Jun 2, 2025, 4:37 PM EDT - 9 months ago

IQVIA Announces Pricing of Senior Notes

Jun 2, 2025, 8:10 AM EDT - 10 months ago

IQVIA Announces Offering of Senior Notes

May 27, 2025, 7:00 AM EDT - 10 months ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

RNTX

May 16, 2025, 8:00 AM EDT - 10 months ago

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

dukewill Mar. 9 at 1:59 PM

$IQV Market shakeout not yet complete

0 · Reply

TheClockworkGroup Feb. 27 at 10:53 PM

0 · Reply

LandonCapital Feb. 25 at 5:30 PM

$IQV https://landoncapital.net/iqvia-nyse-iqv-to-acquire-drug-discovery-assets/

0 · Reply

d_risk Feb. 17 at 4:38 PM

0 · Reply

d_risk Feb. 17 at 3:57 PM

0 · Reply

UgoGreg Feb. 14 at 4:44 PM

$IQV https://youtu.be/m61diFB2Pag

0 · Reply

Estimize Feb. 9 at 3:06 PM

Wall St is expecting 2.84 EPS for $IQV Q1 [Reporting 04/23 BMO] http://www.estimize.com/intro/iqv?chart=historical&metric_name=eps&utm_cont

0 · Reply

ZacksResearch Feb. 5 at 5:52 PM

0 · Reply

ZacksResearch Feb. 5 at 4:52 PM

0 · Reply

1986iamwallstreet Feb. 5 at 2:38 PM

$IQV flush city 🩸🩸🩸🩸🩸🩸

0 · Reply

StocktwitsEarnings Feb. 5 at 12:11 PM

$IQV Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $3.02 up 23.77% YoY • Reported revenue of $4.36B up 10.26% YoY • For full-year 2026, IQVIA expects revenue between $17.15B to $17.35B, Adjusted EBITDA from $3.98B to $4.03B, and Adjusted Diluted Earnings per Share of $12.55 to $12.85.

0 · Reply

1986iamwallstreet Feb. 5 at 12:09 PM

$IQV IQVIA Hldgs Sees FY2026 Adj EPS $12.55-$12.85 vs $12.95 Est; Sees Sales $17.150B-$17.350B vs $17.071B Est 🩸🩸🩸🩸🩸🩸🩸

0 · Reply

AlgorithmAdvisors Feb. 4 at 11:30 AM

$IQV is a leading CRO facing biotech funding headwinds; backlog conversion and large pharma demand provide stability.

0 · Reply

ZacksResearch Feb. 3 at 5:13 PM

Earnings setup for $IQV — growth expectations are heating up 📈 IQV is set to report fourth-quarter 2025 earnings on Feb. 5, with revenues expected to rally 7.2% year over year to $4.2B and EPS expected to rise 9% on segment growth. Full earnings preview and key details here 👉 https://www.zacks.com/stock/news/2828079/iqvia-set-to-report-q4-earnings-heres-what-you-should-know?cid=sm-stocktwits-2-2828079-teaser-31718&ADID=SYND_STOCKTWITS_TWEET_2_2828079_TEASER_31718

0 · Reply

ZacksResearch Feb. 3 at 4:13 PM

$IQV set to report Q4 earnings — will it continue its growth trend? 📊 IQVIA has surpassed the Zacks Consensus Estimate in the last four quarters, averaging a 1.6% surprise. For Q4, revenue is expected to grow 7.2% YoY, with EPS estimated at $3.4, a 9% increase. Discover the full earnings preview here 👉 https://www.zacks.com/stock/news/2828079/iqvia-set-to-report-q4-earnings-heres-what-you-should-know?cid=sm-stocktwits-2-2828079-body-31719&ADID=SYND_STOCKTWITS_TWEET_2_2828079_BODY_31719

0 · Reply

OfficialStocktwitsUser Jan. 27 at 5:51 PM

$IQV RSI: 52.50, MACD: 3.5067 Vol: 6.23, MA20: 237.23, MA50: 229.22 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

AcceleratorModel Jan. 23 at 6:10 AM

$IQV may be time to come back for more

0 · Reply

AcceleratorModel Jan. 23 at 5:31 AM

$IQV Been choppy — but ultimately up and to the right for this name. Haven’t touched it since July ‘25 earnings for a 14% 1 day return. Not looking for a hockey stick here, just a continuation

0 · Reply

rottieluvr3 Jan. 16 at 7:43 PM

$IQV This recently broke resistance, but just barely. Once there is confirmation of a breakout, I’m a buyer.

1 · Reply

ZacksResearch Jan. 15 at 3:26 PM

Data is becoming the next profit engine in medtech — and these names are leading the charge. 📊🧠 $MDT, $IQV and $GEHC are showing how analytics, AI, and enterprise data platforms can be monetized into recurring revenue streams, pushing medical devices beyond just hardware. See how data + AI are reshaping revenue models in medtech 👉 https://www.zacks.com/stock/news/2818016/3-medical-device-companies-in-focus-for-monetizing-data-and-analytics?cid=sm-stocktwits-2-2818016-teaser-29098&ADID=SYND_STOCKTWITS_TWEET_2_2818016_TEASER_29098

0 · Reply

SuperGreenToday Jan. 14 at 7:33 PM

$IQV Share Price: $241.99 Contract Selected: Aug 21, 2026 $250 Calls Buy Zone: $18.02 – $22.26 Target Zone: $32.32 – $39.50 Potential Upside: 69% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BillionerOfKing Jan. 14 at 10:14 AM

$IQV Current Stock Price: $241.63 Contracts to trade: $240 IQV Jan 16 2026 Call Entry: $2.16 Exit: $3.17 ROI: 47% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	29.61B
Revenue (ttm)	16.31B
Net Income (ttm)	1.36B
EPS (ttm)	N/A
PE Ratio	16.42
Forward PE	15.45
Profit Margin	8.34%
Debt to Equity Ratio	2.37

Volume	1,766,000
Avg Vol	2,087,612
Day's Range	N/A - N/A
Shares Out	169.70M
Stochastic %K	63%
Beta	1.39
Analysts	Strong Sell
Price Target	$233.71